61st American Society of Hematology (ASH) Annual Meeting & Exposition

Friday Scientific Workshops: December 6th

1:05 PM-2:05 PM
Location: W230 (Orange County Convention Center)
*Early Life Risk Factors and Early-Onset Non-Hodgkin Lymphoma*
Xiaomei Ma

1:55 PM-2:35 PM
Location: Tangerine 2 (WF2) (Orange County Convention Center)
*METTL3 Mediated m6A RNA Modification Prevents Aberrant Innate Immune Signaling in Fetal Hematopoietic Stem Cells*
Stephanie Halene, MD

3:25 PM-3:55 PM
Location: W230 (Orange County Convention Center)
*NHLBI Myelodysplastic Syndrome Natural History Study: What Are We Learning?*
Steven Gore

3:25 PM-3:55 PM
Location: W230 (Orange County Convention Center)
*Patterns of Care and Comparative Effectiveness in Myelodysplastic Syndrome: Epidemiology of Clinical Intervention*
Rong Wang, PhD

4:10 PM-4:20 PM
W230, Level 2 (Orange County Convention Center)
*Myelodysplastic Syndrome*
Panelists: Steven Gore, and Rong Wang
Friday Satellite Symposia

12:30 PM-4:30 PM
Location: Regency S (Hyatt Regency Orlando)
New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
Speaker: Francine Foss

Career Development Lunch

Saturday, December 7
11:15 AM-12:15 PM
Location: Orlando Ballroom MN (Hyatt Regency Orlando)
Medical Educators in Hematology
Presenter: Alfred Lee

Education Programs:

Saturday, December 7
2:00 PM-3:30 PM
Location: Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Cure at What (Systemic) Financial Cost?
Scott F. Huntington, MD, MPH

Special Scientific Symposia

Saturday, December 7
4:00 PM-5:30 PM
Location: W331 (Orange County Convention Center)
PROTAC-mediated Protein Degradation: A New Therapeutic Modality
Craig Crews

Oral and Poster Abstracts: Saturday, December 7th

9:45 AM
Location: W304, Level 3 (Orange County Convention Center)
Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study
Amer M. Zeidan, Nikolai Podoltsev, Xiaoyi Wang, Jan Philipp Bewersdorf, Rory Shallis, Scott Huntington, Natalia Neparidze, Smith Giri, Steven Gore, Xiaomei Ma, Amy Davidoff, Rong Wang

12:30 PM
Location: Chapin Theater (W320), Level 3 (Orange County Convention Center)
A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Clinically Relevant Abstract
Amer Zeidan

2:15 PM
Location: Chapin Theater (W320) (Orange County Convention Center)
Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDAC) or Decitabine (DEC) in Patients (pts) with Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Amer Zeidan

4:00 PM-5:30 PM
Location: W230, Level 2 (Orange County Convention Center)
Health Services Research—Non-Malignant Conditions: Cancers and Thrombosis
Moderator: Kelsey Martin

5:15 PM
Location: W230, Level 2 (Orange County Convention Center)
Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea
Rong Wang, Rory Shallis, Scott Huntington, Amer Zeidan, Steven Gore, Amy Davidoff, Xiaomei Ma, Nikolai Podoltsev

5:30 PM-7:30 PM
Location: Hall B, Level 2 (Orange County Convention Center)
Baseline Pain in Adults with Sickle Cell Disease Can be Neuropathic or Nociceptive and Outcomes Differ between Pain Types
Susanna Curtis, Ariadna Forray, Jeanne Hendrickson, John Roberts
Developing Single Cell Live Imaging Strategies to Determine MEP Fate and Predict Potential
Vanessa Scanlon, Maria Kochugaeva, Juliana Xavier-Ferrucio, Yi-Chien Lu, Nayoung Kwon, Anisha Laumas, Matthew Cenci, Kalyani Lawrence, Katie Barden, Andre Levchenko, Diane Krause

U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex
Giulia Biancon, Stephanie Halene

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study
Scott Huntington

The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocytopenia
Nikolai Podoltsev, Rong Wang, Rory Shallis, Scott Huntington, Amer Zeidan, Steven Gore, Amy Davidoff, Xiaomei Ma

A Phase I Study of CC-90002, a Monoclonal Antibody Targeting CD47, in Patients with Relapsed and/or Refractory (R/R) Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS): Final Results
Amer Zeidan

Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
Rory Shallis, Jan Philipp Bewersdorf, Lohith Gowda, Nikolai Podoltsev, Thomas Prebet, Steven Gore, Stephanie Halene, Iris Isufi, Francine Foss, Scott Huntington, Tae Kon Kim, Manoj Pillai, Terri Parker, Natalia Neparidze, Noffar Bar, Stuart Seropian, Amer Zeidan

Case Management Featuring Community Health Workers Reduces Inpatient Health Care Utilization in Adults with Sickle Cell Disease
John Roberts

Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
Namrata Chandhok, Wei Wei, Stephanie Halene, Thomas Prebet

_U2AF1 Driver Mutations in Hematopoietic Disorders Alter but Do Not Abrogate RNA Binding and Enlighten Structural Dependencies of the U2AF-RNA Complex_
Giulia Biancon, Stephanie Halene

_Mentorship Experiences Among Second-Year U.S. Hematology/Oncology Fellows in the 2019 ASH Hematology/Oncology Fellows Survey_
Alfred Lee

_Providers Increased the Use of Direct Oral Anticoagulants in Patients with Cancer-Associated Thromboembolism without Gaining Complete Confidence: A Health System-Wide Retrospective Registry Study and a Providers’ Survey_
Alexander Pine, Alfred Lee

**Oral and Poster Abstracts: Sunday, December 8**

**7:45 AM**  
**Location: W315 (Orange County Convention Center)**  
_In Vivo reconstruction of Human Erythropoiesis with Circulating Mature Human RBCs in Humanized Liver Mistrgy Mice_
Yuanbin Song, Stephanie Halene, Richard Flavell

**8:15 AM**  
**Location: Orange County Convention Center, W230**  
_Abatacept Is Effective for Gvhd Prophylaxis after Unrelated Donor Stem Cell Transplantation (URD SCT) for Severe Sickle Cell Disease (SCD)_
Niketa Shah

**1:00 PM**  
**Location: W315 (Orange County Convention Center)**  
_NCOA4 Expression in Hepatic Cells Is Upregulated Under Physiological and Pathophysiological Conditions Associated with Hypoxia_
Xiuqi Li, Larisa Lozovatsky, Karin Finberg

**1:15 PM**  
**Location: W230, Level 2 (Orange County Convention Center)**  
_Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure_
Yimeng Gao, Radovan Vasic, Yuanbin Song, Rhea Teng, Rana Gbyli, Giulia Biancon, Raman Nelakanti, Eriko Kudo, Wei Liu, Anastasia Ardasheva, Xiaoying Fu, Xiaman Wang, Poorval Joshi, Burak Dura, Veronica Lee, Akiko Iwasaki, Rong Fan, Andrew Xiao Richard Flavell, Toma Tebaldi, Stephanie Halene

6:00 PM-8:00 PM
**Location: Hall B, Level 2 (Orange County Convention Center)**

*The Presence and Persistence of Pregnancy-Associated Red Blood Cell Alloantibodies in Blood Donors*
Raisa Balbuena-Merle, Christopher Tormey, Jeanne Hendrickson

*UAF1 DNA Binding Activity Is Critical for RAD51-Mediated Homologous DNA Pairing*
Fengshan Liang, Adam Miller, Caroline Tang, Gary Kupfer

*Potential Overuse of Primary Thromboprophylaxis in Medical Inpatients at Low Risk of Venous Thromboembolism*
Mia Djulbegovic, Kevin Chen, Soundari Sureshanand, Sarwat Chaudhry

*Perceptions and Attitudes Toward Single-Board Hematology Training in the United States: A Program Director Survey*
Alfred Lee

**Special-Interest Sessions: Sunday, December 8**

4:30 PM-6:00 PM
**Location: W304, Level 3 (Orange County Convention Center)**
*The Spirit Catches You and You Fall Down*
Anne Fadiman

**Location: Tangerine 1 (WF1), Level 2 (Orange County Convention Center)**
*How I Setup a Virtual Hematology Consult Service*
Michal Rose

**Oral and Poster Abstracts: Monday, December 9**

7:00 AM
Statewide Intervention to Improve Medical Care Services Utilization Patterns of Adults Living with Sickle Cell Disease
John Roberts, Janis Bozzo, Cindy Du, Susanna A Curtis
7:00 AM
Location: W311EFGH, Level 3 (Orange County Convention Center)
A Phase 1b Study Evaluating the Safety and Efficacy of Venetoclax As Monotherapy or in Combination with Azacitidine for the Treatment of Relapsed/Refractory Myelodysplastic Syndrome
Amer Zeidan
11:15 AM
Location: Tangerine 3 (WF3-4), Level 2 (Orange County Convention Center)
Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States
Amer Zeidan, Rong Wang, Xiaoyi Wang, Rory M Shalis, Nikolai Podoltsev, Jan Philipp Bewersdorf, Scott Huntington, Natalia Neparidze, Smith Giri, Steven Gore, Amy Davidoff, Xiaomei Ma
3:45 PM
Location: Valencia A (W415A), Level 4 (Orange County Convention Center)
Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States
Scott Huntington, Pamela Soulos, Amy Davidoff, Cary Gross
4:30 PM
Location: Chapin Theater (W320), Level 3 (Orange County Convention Center)
Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study
Amer Zeidan
5:45 PM
Location: W304ABCD, Level 3 (Orange County Convention Center)
A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and
Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas
Scott Huntington

6:00 PM-8:00 PM
Location: Hall B, Level 2 (Orange County Convention Center)

Hematologic Immune-Related Adverse Events from Immune Checkpoint Inhibitors: A Systematic Review of Case-Reports and Case-Series
Karthik Gnanapandithan

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Clinically Relevant Abstract
Amer Zeidan

Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation
Namrata S Chandhok, Scott Huntington, Iris Isufi, Lohith Gowda, Mina Xu, Noffar Bar, Stuart Seropian, Francine Foss

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
Rana Gbyli, Yuanbin Song, Wei Liu, Yimeng Gao, Namrata Chandhok, Xiaoying Fu, Xiaman Wang, Amisha Patel, Ranjini SundaramToma Tebaldi, Giulia Biancon, Anastasia Ardasheva, Ashley Qin, Mukhtar Sadykov, Padmavathi Mamillapalli, Richard Flavell, Thomas Prebet, Ranjit Bindra, Stephanie Halene

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of MBG453 Added to Hypomethylating Agents (HMAs) in Patients (pts) with Intermediate, High, or Very High Risk Myelodysplastic Syndrome (MDS): Stimulus-MDS1
Amer Zeidan

Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)
Program: Oral and Poster Abstracts
Xiaoyi Wang, Rong Wang, Chi Zhang, Amer Zeidan, Nikolai Podoltsev, MD, Scott Huntington, Steven Gore, Amy Davidoff, Xiaomei Ma
The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Namrata S Chandhok, Wei Wei, Ranjit Bindra, Stephanie Halene, Thomas Prebet

Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia
Amer Zeidan

Spotlight Sessions

Monday, December 9
2:45 PM-4:15 PM
Location: W312, Level 3 (Orange County Convention Center)
Levamisole and Cocaine: Contaminants in Illicit Drugs and Hematologic Complications
Daniel Glenn Federman